Licensing & Development
Total Trials
1
As Lead Sponsor
0
As Collaborator
Total Enrollment
313
NCT03384745
A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe Psoriasis
Phase: Phase 2
Role: Collaborator
Start: Jul 31, 2018
Completion: Mar 26, 2020
Loading map...